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Abstract: Purpose/Background
Clozapine is associated with haematological abnormalities, with neutropenia and
agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has
been used to support clozapine rechallenge following neutropenia with the aim of
maintaining the neutrophil count. This study aims to explore the practice, use, safety
and efficacy of G-CSF in this context.
Methods/Procedures
We conducted a systematic review to identify all studies investigating or describing G-
CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge.
Findings/Results
We identified 32 reports of patients who received G-CSF either regularly (n = 23), or as
required (n = 9) to support clozapine rechallenge following an episode of neutropenia
necessitating discontinuation of clozapine.  Seventy-five percent (n=24) of published
cases remained on clozapine with the use of continual prophylactic G-CSF or after
single G-CSF administrations (N=8). Seventy percent (n=16) of cases in receipt of
continual prophylactic G-CSF were successfully maintained on clozapine. However,
one of the three episodes of rechallenge in those with a history of severe
agranulocytosis (ANC <0.1x109/L) had a recurrence of agranulocytosis at week 9.
Implications/Conclusions
Our findings suggest that GCSF can sometimes be safely used to support the
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
maintenance of normal neutrophil counts and clozapine use post-neutropenia.
Publication bias is an important limitation, however. Also, few reports clearly
documented the presence or absence of an independent non-clozapine cause of the
index neutropenia, which may have increased success rates.  Furthermore, adverse
events were not systematically recorded.  Prospective studies are needed to determine
safety, as if agranulocytosis occurs on clozapine while supported by G-CSF, there is
no obvious alternate rescue therapy to promote granulopoiesis. From the available
data, it is not possible to recommend this course of action for someone with a true
clozapine agranulocytosis.
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Running title: 
Granulocyte colony-stimulating factor in clozapine rechallenge  
 
Purpose/Background 
Clozapine is associated with haematological abnormalities, with neutropenia and 
agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been 
used to support clozapine rechallenge following neutropenia with the aim of maintaining the 
neutrophil count. This study aims to explore the practice, use, safety and efficacy of G-CSF 
in this context.  
Methods/Procedures 
We conducted a systematic review to identify all studies investigating or describing G-CSF 
as a prophylaxis to enable continued clozapine treatment during a rechallenge.  
Findings/Results 
We identified 32 reports of patients who received G-CSF either regularly (n = 23), or as 
required (n = 9) to support clozapine rechallenge following an episode of neutropenia 
necessitating discontinuation of clozapine.  Seventy-five percent (n=24) of published cases 
remained on clozapine with the use of continual prophylactic G-CSF or after single G-CSF 
administrations (N=8). Seventy percent (n=16) of cases in receipt of continual prophylactic 
G-CSF were successfully maintained on clozapine. However, one of the three episodes of 
rechallenge in those with a history of severe agranulocytosis (ANC <0.1x109/L) had a 
recurrence of agranulocytosis at week 9. 
Implications/Conclusions 
Manuscript
Our findings suggest that GCSF can sometimes be safely used to support the maintenance 
of normal neutrophil counts and clozapine use post-neutropenia. Publication bias is an 
important limitation, however. Also, few reports clearly documented the presence or absence 
of an independent non-clozapine cause of the index neutropenia, which may have increased 
success rates.  Furthermore, adverse events were not systematically recorded.  Prospective 
studies are needed to determine safety, as if agranulocytosis occurs on clozapine while 
supported by G-CSF, there is no obvious alternate rescue therapy to promote 
granulopoiesis. From the available data, it is not possible to recommend this course of action 
for someone with a true clozapine agranulocytosis.  
Keywords: granulocyte colony stimulating factors; G-CSF; GM-CSF; treatment-resistant; 
schizophrenia; clozapine; neutropenia; agranulocytosis  
Introduction 
Clozapine remains the gold standard treatment for treatment resistant schizophrenia (TRS) 
(1) and is associated with clinical response in 50-60% of patients with TRS.(2, 3) However, 
its use is restricted due to the risk of potentially life-threatening adverse events. (4)  In 
particular, clozapine use has a risk of agranulocytosis, and in many countries, the 
emergence of neutropenia, which can presage agranulocytosis, means that clozapine must 
be discontinued.(5)  
Rechallenge after clozapine associated neutropenia carries significant risk, especially 
following an episode of clozapine-associated agranulocytosis (CIA)  where recurrence of 
neutropenia on rechallenge occurs in 80% of patients in contrast to 30% following a 
neutropenia-related discontinuation.(6) In an earlier retrospective case review, 38% of cases 
overall developed a neutropenia on clozapine rechallenge, and for 85% of these the 
neutropenia occurred more quickly and was more severe than during the first clozapine trial. 
Further, for 65% of the cases who developed a further neutropenia on rechallenge, the 
neutropenia was longer in duration than the original episode.(7) 
More recently, granulocyte colony-stimulating factors (G-CSFs), and granulocyte-
macrophage colony-stimulating factors (GM-CSFs) have been used in specialist centres with 
the aim of preventing the recurrence of neutropenia on clozapine rechallenge. However, this 
practice has not been systematically reviewed.  
Therefore, in this study we aimed to synthesize the published data in order review the 
efficacy of G-CSF during clozapine rechallenge for the prevention of recurrence of clozapine 
associated neutropenia or agranulocytosis, to describe the dose and frequency of G-CSF 
used and to review adverse incidents. 
Methods 
We performed a systematic literature search to identify all published interventional and 
observational studies, case series and case reports, up until September 2016, investigating 
or describing G-CSF use as either a regular or as required (PRN) administrations, to support 
resumption and maintenance of clozapine treatment. We defined as required administrations 
as those cases in which there was an a priori plan to administer G-CSF in single or 
consecutive G-CSF doses in the event of a neutropenic episode (as defined by the individual 
case reports), and where G-CSF was discontinued upon neutrophil recovery. Regular 
administration was defined as regular use of prophylactic G-CSF; even where the neutrophil 
count was normal or high. This systematic review was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standard. 
(8)  
Inclusion criteria 
Studies were included in this systematic review if they included: (1) participants (no age 
restriction) who had a clozapine rechallenge after an episode of clozapine associated 
neutropenia; (2) participants who were treated prophylactically with regular G-CSF, or with 
as required administrations of G-CSF to enable continued clozapine use during rechallenge; 
and (3) were published in a peer reviewed journal.  
Exclusion criteria 
Studies were excluded if:  (1) G-CSF was used to support the maintenance of clozapine 
treatment during chemotherapy; (2) if there were insufficient laboratory data to permit 
inclusion of the report and; (3) if G-CSF was not used to support continued clozapine use 
during a rechallenge. 
Information sources and searches 
Two independent reviewers (JL & SM) performed a search using Medline, EMBASE, Scopus 
and Google Scholar from inception until September 2016. The following search terms were 
used, both alone and in combinations: Granulocyte Colony-Stimulating Factor OR 
granulocyte-macrophage colony-stimulating OR GCSF OR G-CSF OR GMCSF OR GM-CSF 
AND clozapine  OR  clozaril  OR  denzapine  OR  zaponex OR leponex. 
In addition, the reference lists of the retrieved articles and relevant review articles were 
examined for cross-references. 
Study selection and exclusion 
All abstracts meeting the criteria were obtained, and independently examined by the authors 
(JL and SM). The two appraisers applied the eligibility criteria to produce a list of full text 
articles. There was no search for unpublished works, although authors were contacted for 
clarification where necessary. Reference lists were searched for additional studies.  
Primary outcome 
The primary outcome was the continuation of clozapine with white cell and neutrophil count 
within the allowed ranges for continued clozapine prescription (i.e. WCC>3.0 x109/L and 
ANC>1.5x109/L) at the end of follow-up which was designated a “successful outcome”.  
Secondary outcomes 
Since filgrastim was the most common drug used, we examined for associations between 
the dose of filgrastim used and successful outcome. We recorded successful rechallenge 
rates for patients where the index episode was agranulocytosis (absolute neutrophil count 
<0.5 x109 ) or  severe agranulocytosis (ANC < 0.1x109/L).  
Data extraction 
Articles included were critically reviewed by two authors (JL and SM) and the following 
information extracted where possible: age, gender, ethnicity, number of previous clozapine 
(re-)challenges, severity of initial neutropenia, G-CSF/GM-CSF dose, frequency and type of 
G-CSF used; duration of follow up; and successful outcome, defined as continuation of 
clozapine treatment or not, alternative causes of neutropenia, and adverse events. We did 
not undertake a risk of bias assessment of the included studies, as the majority were case 
series/reports.  
Results 
Study selection, study and participant characteristics 
The study selection process, search results, and reasons for exclusion are given in figure 1. 
The initial search yielded 766 references. After checking titles and abstracts, 57 full texts 
were screened. This selection process refined the number of relevant articles to 16 clinical 
reports, 6 of which were case series and 10 of which were case reports. No interventional or 
observational studies were identified. 
We identified 32 episodes(in 31 patients) of clozapine re-challenge, where G-CSF was 
prescribed as maintenance prophylaxis (n=23)(9-19) or as single, as required 
administrations (n=9)(13, 14, 20-24) to enable continued clozapine treatment.  
Cause of the initial neutropenic episode 
An appraisal of potential alternative explanations for the initial neutropenia (eg viral illness, 
other drug treatments) was documented in 6 of the 32 cases. Four cases provided sufficient 
information to indicate that a ‘true’ clozapine induced neutropenia or agranulocytosis had 
occurred,(9, 17, 20, 24) while in two cases, other contributing factors were identified. (15, 19) 
G-CSF in clozapine rechallenge 
Twenty-three of the 32 cases identified received continual G-CSF as prophylaxis (mean 
duration of G-CSF use: 8.8 (4.2) months, median =11 months; range 1.25-13 months), while 
9 received GCSF as required (there were no cases reported where as required G-CSF was 
prescribed but not administered). 
Seventy five percent (n=24) of cases remained on clozapine with the support of regular G-
CSF (n=16) or after as-required G-CSF administrations (n=8) (mean duration of follow up: 
11.8 (5.4) months, median =12 months; range 5-30 months), while in 25% (n=8) of cases 
clozapine was discontinued due to recurrence of neutropenia, or an attenuated response to 
G-CSF suggesting an enhanced risk of agranulocytosis leading to a clinician initiated 
discontinuation. Seventy percent (n=16) of cases in receipt of continual prophylactic G-CSF 
were successfully maintained on clozapine for an average follow up period of 10.9 (SD = 
2.5) months (median 12 months; range 5-13 months). The mean time to clozapine 
discontinuation in those treated with continual G-CSF (n=6) was 3.0 (2.8) months (range 
=0.25-7 months). Seventy-eight percent were treated with filgrastim (n=25), 16% were 
treated with lenograstim (n=5) while the other two cases were treated with G-CSF 
(formulation not specified) and GM-CSF. Fifteen cases received G-CSF weekly and seven 
twice weekly, with two receiving filgrastim 480mcg daily. Seventy one percent of those 
treated with continual filgrastim (n=15) and 50% of those treated with continual lenograstim 
remained on clozapine (n=1). The characteristics of G-CSF use and associations with 
continued clozapine use are show in table 1.  
Seventy-four per cent of cases where sex was specified were male (17 / 23), with 76% of 
white ethnicity (n=19) and 20% of black ethnicity (n=5). Eighty-four percent (n=16/19) of 
those of white ethnicity remained on clozapine compared to 60% (n=3/5) of those of black 
ethnicity.  
Previous neutropenic episode and outcomes during rechallenge 
Data were available for 17 of the cases regarding the degree of neutropenia at the index 
clozapine discontinuation, with seven cases having had agranulocytosis (ANC 0.1-
0.5x109/L), three with severe agranulocytosis (ANC <0.1x109/L), while the other seven had 
neutropenia (ANC 0.5-1.5 x109/L). All those with a documented ANC < 0.5x109/L were 
prescribed continual G-CSF prophylaxis during rechallenge. Three from seven cases with a 
prior agranulocytosis failed rechallenge, as did one third (1/3) of those with a prior history of 
severe agranulocytosis. One case with an index episode of severe agranulocytosis had a 
recurrence of agranulocytosis (ANC =0.3x109/L), on a first rechallenge, while treated with G-
CSF 300mcg twice weekly, subsequently had a second rechallenge, supported on G-CSF 
480 mcg twice weekly, and was successfully maintained on clozapine at the time of follow 
up(12.5 months), (mean ANC, =15.8 x109/L; median ANC=10.5 x109/L; range ANC= 3.7 
x109/L –51.3 x109. (17) 
Adverse events 
Only nine cases reported on adverse events relating to G-CSF use. Two had evidence of a 
rebound leucocytosis, (15, 20) while in another case, a mild subjective euphoria in the hours 
post G-CSF administration was reported.(9) The other six cases did not have any adverse 
events associated with G-CSF use. (13, 18, 22, 24) 
Discussion 
In this first systematic review of the use of G-CSF to support clozapine re-challenge and 
maintenance, it appears that G-CSF is an effective strategy for some people. Seventy-five 
percent of cases were able to continue clozapine with the use of G-CSF, either as regular 
prophylaxis (70% success rate) or as required administrations (89% success rate). 
Our review findings provide the largest synthesis of cases where G-CSF has been used to 
prevent recurrence of neutropenia and/or to allow for the continuation of clozapine. In the 
majority of published cases the use of G-CSF enabled clozapine to be continued for at least 
10 months. This is in keeping with a recent systematic review, where clozapine rechallenge 
was successful in 78/112 patients (70 %) after neutropenia.(6) We identified that 60% of 
those with an index episode of agranulocytosis had a successful outcome with continual G-
CSF use, a higher figure than the 3/15 patients (20 %) with a successful rechallenge after 
agranulocytosis in the review of Manu et al. That same review examined 11 cases of 
rechallenge after neutropenia in which seven patients successfully continued clozapine while 
receiving G-CSF.(6) Our review expands on this by identifying 32 episodes in which G-CSF 
was used to support clozapine rechallenge or clozapine continuation in cases where low 
neutrophil counts led to interruption of treatment.  
Rechallenge after neutropenia or agranulocytosis is a risky enterprise and a complex clinical 
decision, especially as the long term consequences of maintenance G-CSF treatment in the 
absence of a primary haematological problem are unclear. Nevertheless, our findings 
suggest that, in some cases, G-CSF can be successfully used to facilitate the successful re-
initiation and maintenance of clozapine, although there is insufficient data systematically 
examining adverse outcomes to be able to comment authoritatively on safety.   
Limitations 
Our findings must be viewed in relation to limitations in the primary study data. Only 6 of the 
reported cases provided an evaluation for non-clozapine related causes of the initial 
neutropenia event. This raises the possibility that some of the index events may not have 
been a true clozapine induced neutropenia, but neutropenia secondary to alternative non 
clozapine factors, a commonly encountered scenario in specialist clinical practice. The risk 
of neutropenia recurrence during clozapine rechallenge depends on whether the index event 
was truly caused by clozapine or not. The paucity of data relating to this important factor in 
the cases identified in this review, means that some of the cases reported may not represent 
true clozapine-induced neutropenia. Any non-clozapine related neutropenic and 
agranulocytosis episodes, may have contributed to the successful rechallenge, raising the 
possibility of an overestimation of the rate of successful rechallenge.  
There were no controlled studies available, and there is a need for caution in interpreting 
data relating to case reports and case series.(25) Case reports alone cannot provide an 
accurate or quantitative measure of the risk for complications or death associated with a 
drug or treatment intervention such as this. A publication bias in favour of cases in which 
rechallenge was successful is probable. Furthermore, unreported deaths or severe adverse 
reactions may have occurred during the use of G-CSF. A prospective placebo controlled trial 
to establish the efficacy of G-CSF in clozapine rechallenge would be the gold standard 
approach to establish this, though the rarity of clozapine rechallenge may make such a study 
impractical outside highly specialised centres.  As such, multicentre observational and 
retrospective studies to establish the efficacy of G-CSF in clozapine associated 
agranulocytosis would be the first choice for future research. 
Conclusions 
We provide further evidence that the use of G-CSF can support successful clozapine 
rechallenge after discontinuation because of an episode of neutropenia/agranulocytosis. 
However, given the paucity of systematically reported data on this topic and the reliance on 
case reports which may be subject to publication bias, these results should be interpreted 
with caution.  From the available data, it is not possible to recommend this course of action 
for someone with a true clozapine agranulocytosis.  
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Table 1. Characteristics of G-CSF use for those remaining on clozapine during rechallenge  
 All patients Remained on 
clozapine 
Clozapine 
discontinued  
X 2 /T test; p value 
Remained on clozapine: 
Continual G-CSF, n (%) 
G-CSF as required, n (%) 
 
23 (72) 
9 (28) 
24 (75%) 
16 (70) 
8 (89) 
8 (25%) 
7 (30) 
1 (11) 
 
G-CSF used: 
Filgrastim, n (%) 
Lenograstim, n(%) 
 
25 
5 
 
19 (76) 
3 (60) 
 
6 (24) 
2 (40) 
 
0.545; 0.405 
Filgrastim mean  (SD) 
weekly dose mcg/week 
680.4 (710.6) 504 (227.3) 450 (173.1) 0.434; 0.670 
Filgrastim dose/week: 
>300mcg/week, n (%) 
≤  300mcg/week, n(%) 
 
11 
12 
 
9 (82) 
8 (67) 
 
2 (18) 
4 (33) 
 
0.683; 0.365 
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RE: The use of G-CSF in clozapine rechallenge: a systematic review 
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Mijovic, James H MacCabe. 
Thank you for your email on the 28th April 2017 requesting a 
revision of the article ‘The use of G-CSF in clozapine rechallenge: a 
systematic review’, subsequent to the first review process. We 
have enclosed a revised version of this manuscript. We believe all 
of the reviewer’s concerns have been addressed in this version 
and we hope that it may now be accepted by the Journal of 
Clinical Psychopharmacology. We have retained our cautious 
approach regarding the use of G-CSF in clinical practice for 
clozapine rechallenge which is highlighted in our abstract and in 
the conclusion to our discussion.   
This article is not currently under consideration for publication in 
another journal. The conflict of interest statement is complete 
within the electronic submission. All authors have contributed 
significantly; all authors are in agreement with the content of the 
manuscript. Below is our response to the reviewers’ comments. 
We thank you for kindly considering our paper and hope to hear 
from you soon.  
Best wishes,  
Cover Letter
Dr John Lally on behalf of all authors.  
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Comments of the 2 Reviewers: 
 
Reviewer #1:  
 
The only problem that I have with it is the following statement:  
 
"There are no clear criteria for clozapine rechallenge where clozapine treatment is suspended 
following neutropenia,(25)".  
 
If I am interpreting the recently enacted Clozapine REMS Program correctly, it states clear criteria 
for clozapine re-challenges. 
 
Response: JL et al –We thank the reviewer for their expert comment. We agree that this 
statement is ambiguous, and in light of the recent clozapine REMs program is inaccurate 
in relation to neutropenia. We have now removed the statement from our discussion. 
 
Reviewer #2:  
 This is a worthwhile contribution to the question of successful rechallenge with clozapine after 
neutropenia or agranulocytosis. However, I consider that it could be substantially shortened (to 
50%) and that this would improve the message. 
 
The substantial proportion of the data on page 7 (results) could be presented more helpfully in a 
table. 
 
Response: JL et al: We thank the reviewer for highlighting this. We have included a 
table, in place of some of the results, specifically in relation to associations with G-CSF 
formulation and doses used and favourable outcomes. We hope that this is acceptable.  
A cost-effectiveness analysis would add value. 
 
Response: JL et al. We agree with the reviewer that this would be an interesting addition 
to the study, but we have not sought to conduct such an analysis based on the data 
available to use in this review.  
 
Page 4, adverse incidences should be adverse events or adverse incidents. 
 
Page 7, 'or an attenuated response to G-CSF, which, although not breaching licensing 
requirements, suggested an enhanced risk of agranulocytosis leading to a clinician initiated 
discontinuation.' is a bit turgid. Mention of the licensing requirements doesn't help and isn't 
relevant.  
 
JL et al –We have updated the manuscript in relation to both of the above points. 
 
 
Page 9, 'In the majority of published cases the use of G-CSF enabled clozapine to be continued 
for at least 18 months.' The results indicate successful continuation for up to 13 months. Is this an 
error, or does it come from somewhere else or what? Please clarify. 
 
JL et al –We thank the reviewer for noting this. This is an error and should read 10 
months.  
 
Page 10, 'Most patients with clozapine rechallenge are not reported in the literature..' you can't 
make a statement like this without a reference. This is sufficient 'A publication bias in favour of 
cases in which [there is a favourable outcome] rechallenge was successful is probable.' 
 
JL et al –We thank the reviewer for this suggestion and have updated as follows: 
“A publication bias in favour of cases in which rechallenge was successful is probable.” 
 
Page 10, the last sentence is incomplete. Is a prospective placebo controlled trial a realistic 
expectation? Perhaps a system of canvassing psychiatric services for cases of rechallenge is a 
more likely option. 
 
JL et al –We thank the reviewer for highlighting this omission. This is now corrected and 
reads as follows: 
“A prospective placebo controlled trial to establish the efficacy of G-CSF in clozapine 
rechallenge would be the gold standard approach to establish this, though the rarity of 
clozapine rechallenge may make such a study impractical outside highly specialised 
centres.  As such, multicentre observational and retrospective studies to establish the 
efficacy of G-CSF in clozapine associated agranulocytosis would be the first choice for 
future research.” 
 
-- 
 
 
JL et al –We thank the expert reviewer for their comments that have improved the 
quality of our work.   
 
